Caduet in an Untreated Subject Population

Completed · Phase 4

Conditions studied: Hypertension, Dyslipidemia

In brief

The purpose of this study is to determine if Caduet will lower blood pressure to \<140/90 mmHg and lower LDL Cholesterol to \<100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these medical conditions.

Key facts

Study ID

NCT00332761

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

220

Starts

2006-06-01

Expected to finish

2007-09-01

Last updated by the study team

2021-01-27

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects who were recently diagnosed with both hypertension and dyslipidemia and who are not yet taking any medications for these conditions OR subjects with both hypertension and dyslipidemia who were previously treated with antihypertensive and/or lipid lowering medications but discontinued these medications for at least 3 months prior to the Screening visit.
• SBP 140-169 mmHg and/or DBP 90-105 mmHg, LDL-C 110-160 mg/dL

You may not qualify if…

• Subjects with a history of MI, angina, coronary artery bypass or intra-coronary interventions, stroke, TIA, CHF or cardiomyopathy requiring treatment.
• Subjects with a known history of Type I or Type 2 Diabetes Mellitus or a fasting blood glucose > 126 mg/dL at the Screening visit.

Where it is running

• Pfizer Investigational Site — Jonesboro, Arkansas, United States
• Pfizer Investigational Site — Little Rock, Arkansas, United States
• Pfizer Investigational Site — Garden Grove, California, United States
• Pfizer Investigational Site — Long Beach, California, United States
• Pfizer Investigational Site — Tustin, California, United States
• Pfizer Investigational Site — Aventura, Florida, United States
• Pfizer Investigational Site — Fort Lauderdale, Florida, United States
• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Pembroke Pines, Florida, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Decatur, Georgia, United States
• Pfizer Investigational Site — Bossier City, Louisiana, United States
• Pfizer Investigational Site — Fair Haven, Michigan, United States
• Pfizer Investigational Site — Livonia, Michigan, United States
• Pfizer Investigational Site — Jackson, Mississippi, United States
• Pfizer Investigational Site — Jackson, Mississippi, United States
• Pfizer Investigational Site — Excelsior Springs, Missouri, United States
• Pfizer Investigational Site — Berlin, New Jersey, United States
• Pfizer Investigational Site — Elizabeth, New Jersey, United States
• Pfizer Investigational Site — Princeton, New Jersey, United States
• Pfizer Investigational Site — South Bound Brook, New Jersey, United States
• Pfizer Investigational Site — Binghamton, New York, United States
• Pfizer Investigational Site — Monroe, North Carolina, United States
• Pfizer Investigational Site — Winston-Salem, North Carolina, United States
• Pfizer Investigational Site — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.